NCT00309452

Brief Summary

The purpose of this study is to understand the effectiveness of a specialized package of phase-specific treatments for individuals in the midst of their first episode of psychosis. The pharmacologic and psychosocial treatments will be delivered within a state public mental health center.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2006

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

March 29, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 31, 2006

Completed
7.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
3.3 years until next milestone

Results Posted

Study results publicly available

October 31, 2016

Completed
Last Updated

February 8, 2017

Status Verified

December 1, 2016

Enrollment Period

7.4 years

First QC Date

March 29, 2006

Results QC Date

May 25, 2016

Last Update Submit

December 12, 2016

Conditions

Keywords

First episode psychosisSpecialized carePhase-specific treatmentSchizophreniaDisorders with psychotic features

Outcome Measures

Primary Outcomes (1)

  • Number of Patients Hospitalized

    1 year after enrollment

Secondary Outcomes (10)

  • Relapse

    every 6 months

  • Overall Functioning- Global Assessment of Functioning

    12 months

  • Quality of Life- Heinrich's Quality of Life Scale

    12 months

  • Vocationally Engaged

    1 year after enrollment

  • Treatment Satisfaction

    every 6 months

  • +5 more secondary outcomes

Study Arms (2)

Treatment as usual

ACTIVE COMPARATOR

Referral to community providers.

Other: Treatment as Usual in the community

STEP Care

EXPERIMENTAL

Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.

Behavioral: Cognitive Behavioral Group TherapyBehavioral: Cognitive remediationDrug: MedicationsBehavioral: MFGBehavioral: Assertive case management

Interventions

once per week

STEP Care

as needed

STEP Care

Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.

STEP Care
MFGBEHAVIORAL

Multi-Family psychoeducation Group based on the model published by McFarlane et al.

STEP Care

Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.

STEP Care

Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.

Treatment as usual

Eligibility Criteria

Age16 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 16-45
  • Meets DSM-IV schizophrenia spectrum psychosis or affective psychosis according to the SCID
  • ≤8 weeks of received antipsychotic treatment lifetime at time of referral
  • Willing to be treated in New Haven

You may not qualify if:

  • Psychosis believed due to substance use (based on the SCID)
  • Unable or unwilling to give informed consent
  • MR as indicated by receipt of services from Dept of Mental Retardation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Connecticut Mental Health Center

New Haven, Connecticut, 06519, United States

Location

Related Publications (12)

  • Srihari VH, Breitborde NJ, Pollard J, Tek C, Hyman L, Frisman LK, McGlashan TH, Jacobs S, Woods SW. Public-academic partnerships: early intervention for psychotic disorders in a community mental health center. Psychiatr Serv. 2009 Nov;60(11):1426-8. doi: 10.1176/appi.ps.60.11.1426.

    PMID: 19880454BACKGROUND
  • Breitborde NJ, Woods SW, Srihari VH. Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysis. Psychiatr Serv. 2009 Nov;60(11):1477-83. doi: 10.1176/ps.2009.60.11.1477.

    PMID: 19880465BACKGROUND
  • Breitborde NJ, Srihari VH, Pollard JM, Addington DN, Woods SW. Mediators and moderators in early intervention research. Early Interv Psychiatry. 2010 May;4(2):143-52. doi: 10.1111/j.1751-7893.2010.00177.x.

    PMID: 20536970BACKGROUND
  • Saksa JR, Cohen SJ, Srihari VH, Woods SW. Cognitive behavior therapy for early psychosis: a comprehensive review of individual vs. group treatment studies. Int J Group Psychother. 2009 Jul;59(3):357-83. doi: 10.1521/ijgp.2009.59.3.357.

    PMID: 19548785BACKGROUND
  • Breitborde NJ, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosis. Early Interv Psychiatry. 2009 Nov;3(4):259-65. doi: 10.1111/j.1751-7893.2009.00148.x.

    PMID: 22642728BACKGROUND
  • Srihari VH, Shah J, Keshavan MS. Is early intervention for psychosis feasible and effective? Psychiatr Clin North Am. 2012 Sep;35(3):613-31. doi: 10.1016/j.psc.2012.06.004. Epub 2012 Jul 21.

    PMID: 22929869BACKGROUND
  • Ozkan B, Phutane V, Jonas E, Tek C, Srihari V. Hoofbeats and zebras: neurodegenerative disorder presenting as a "first episode" of psychosis. Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):412.e1-3. doi: 10.1016/j.genhosppsych.2011.03.011. Epub 2011 May 5.

    PMID: 21762843BACKGROUND
  • Dodds TJ, Phutane VH, Stevens BJ, Woods SW, Sernyak MJ, Srihari VH. Who is paying the price? Loss of health insurance coverage early in psychosis. Psychiatr Serv. 2011 Aug;62(8):878-81. doi: 10.1176/ps.62.8.pss6208_0878.

  • Perez VB, Ford JM, Roach BJ, Woods SW, McGlashan TH, Srihari VH, Loewy RL, Vinogradov S, Mathalon DH. Error monitoring dysfunction across the illness course of schizophrenia. J Abnorm Psychol. 2012 May;121(2):372-87. doi: 10.1037/a0025487. Epub 2011 Nov 7.

  • Breitborde NJ, Kleinlein P, Srihari VH. Self-determination and first-episode psychosis: associations with symptomatology, social and vocational functioning, and quality of life. Schizophr Res. 2012 May;137(1-3):132-6. doi: 10.1016/j.schres.2012.02.026. Epub 2012 Mar 22.

  • Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, Srihari VH. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res. 2011 Apr;127(1-3):257-61. doi: 10.1016/j.schres.2010.12.008. Epub 2011 Jan 15.

  • Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJ, Pollard J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. Psychiatr Serv. 2015 Jul;66(7):705-12. doi: 10.1176/appi.ps.201400236. Epub 2015 Feb 2.

Related Links

MeSH Terms

Conditions

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia

Interventions

Cognitive RemediationDosage FormsTherapeutics

Condition Hierarchy (Ancestors)

Mental Disorders

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and ActivitiesPharmaceutical PreparationsTechnology, PharmaceuticalInvestigative Techniques

Results Point of Contact

Title
Vinod H. Srihari
Organization
Yale University

Study Officials

  • Vinod H Srihari, M.D.

    Yale University School of Medicine & Connecticut Mental Health Center

    PRINCIPAL INVESTIGATOR
  • Scott Woods, M.D.

    Yale University

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 29, 2006

First Posted

March 31, 2006

Study Start

March 1, 2006

Primary Completion

August 1, 2013

Study Completion

August 1, 2013

Last Updated

February 8, 2017

Results First Posted

October 31, 2016

Record last verified: 2016-12

Locations